达格列净或格列齐特缓释片联合甘精胰岛素在2型糖尿病患者中的疗效和安全性比较  

Comparison on the Effect and Safety of Dapagliflozin or Gliclazide Sustained Release Tablets Combined with Insulin Glargine in the Patients with Type 2 Diabetes Mellitus

作　　者：孙军卫[1] 俞海燕[1] 张晓兰[1] SUN Junwei;YU Haiyan;ZHANG Xiaolan(The People’s Hospital of Jiangyin City,Jiangyin 214400,China)

机构地区：[1]江阴市人民医院,江苏江阴214400

出　　处：《中外医学研究》2020年第28期1-4,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：徐州医科大学高等教育教改研究课题项目(Xjylczx201904);徐州市科学技术局应用基础研究计划项目(KC18056)。

摘　　要：目的:观察与比较达格列净或格列齐特缓释片联合甘精胰岛素在2型糖尿病患者中的疗效和安全性。方法:选取2019年1月-2020年1月的80例2型糖尿病患者为研究对象,将其随机分为A组(格列齐特缓释片联合甘精胰岛素)40例和B组(达格列净联合甘精胰岛素)40例。比较两组治疗前后的血糖水平、糖化血红蛋白水平、血糖变异性指标、血管内皮损伤指标及不良反应发生率。结果:治疗前两组血糖水平、糖化血红蛋白水平、血糖变异性指标及血管内皮损伤指标比较,差异均无统计学意义(P>0.05);治疗后4周及12周两组的上述指标均显著降低,两组间糖水平、糖化血红蛋白水平比较,差异均无统计学意义(P>0.05),而B组的血糖变异性指标及血管内皮损伤指标显著低于A组,差异均有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达格列净与格列齐特缓释片分别联合甘精胰岛素在2型糖尿病患者中的疗效和安全性均较好,而达格列净联合甘精胰岛素在血糖变异性控制及血管内皮受损改善方面效果更好。Objective:To observe and compare the effect and safety of Dapagliflozin or Gliclazide Sustained Release Tablets combined with Insulin Glargine in the patients with type 2 diabetes mellitus.Method:A total of 80 patients with type 2 diabetes mellitus from January 2019 to January 2020 were chosen as the research object,and they were randomly divided into group A (Gliclazide Sustained Release Tablets combined with Insulin Glargine) of 40 cases and group B (Dapagliflozin combined with Insulin Glargine) of 40 cases.Then the blood glucose levels,glycosylated hemoglobin levels,vascular endothelial injury indexes and blood glucose variability indexes before and after the treatment,adverse reactions rates of two groups were compared.Result:The blood glucose levels,glycosylated hemoglobin levels,blood glucose variability indexes and vascular endothelial injury indexes of two groups before the treatment were compared,there were no statistically significant differences (P>0.05),those indexes of two groups at 4th and 12th weeks after the treatment significantly decreased,and the blood glucose levels,glycosylated hemoglobin levels and vascular endothelial injury indexes of two groups were compared,there were no statistically significant differences (P>0.05),while the blood glucose variability indexes of group B were significantly lower than those of group A,there were statistically significant differences (P<0.05).The adverse reactions rates of two groups were compared,and there was no statistically significant difference (P>0.05).Conclusion:The effect and safety of Dapagliflozin or Gliclazide Sustained Release Tablets combined with Insulin Glargine in the patients with type 2 diabetes mellitus are both good,and the control effect of Dapagliflozin combined with Insulin Glargine for blood glucose variability and improvement for vascular endothelial injury is better.

关 键 词：达格列净 格列齐特缓释片 甘精胰岛素 2型糖尿病 疗效 安全性 血糖变异性 血管内皮损伤 

分 类 号：R587.1[医药卫生—内分泌]